LINCOLN
Lincoln Pharmaceuticals Limited (LINCOLN) Stock Analysis
Lincoln Pharmaceuticals Limited is an Indian pharmaceutical company manufacturing formulations in antibiotics, gastro, and other therapies for domestic and export markets. It operates regulated manufacturing facilities and markets through a field force. The company competes in India's generic medicines market. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹558.30
-4.08% 1W | +6.60% 52W
Market Cap
1.1k CR
P/E Ratio
11.6
52W High
₹770
52W Low
₹440
Div. Yield
0.32%
Beta
0.5
50 DMA
₹603.1
200 DMA
₹594.2
Profit Margin
13.9%
Inst. Own.
0.8%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 136 | 156 | 146 | 142 | 147 | 161 | 147 | 168 | 154 | 163 | 166 | 187 | 177 |
| Expenses | 115 | 125 | 117 | 124 | 125 | 133 | 123 | 141 | 130 | 138 | 143 | 162 | 150 |
| Operating Profit | 21 | 31 | 30 | 18 | 23 | 28 | 24 | 27 | 24 | 25 | 24 | 25 | 27 |
| OPM % | 15% | 20% | 20% | 13% | 15% | 18% | 16% | 16% | 15% | 16% | 14% | 13% | 15% |
| Other Income | 8 | 9 | 11 | 7 | 10 | 10 | 9 | -7 | 15 | 7 | 15 | -4 | 24 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 |
| Profit before tax | 25 | 37 | 38 | 22 | 29 | 35 | 29 | 16 | 35 | 29 | 35 | 17 | 48 |
| Tax % | 25% | 25% | 26% | 16% | 20% | 24% | 28% | 29% | 22% | 31% | 18% | 30% | 24% |
| Net Profit | 19 | 28 | 28 | 19 | 24 | 26 | 21 | 12 | 28 | 20 | 29 | 12 | 36 |
| EPS in Rs | 9.49 | 13.80 | 14.00 | 9.29 | 11.82 | 13.15 | 10.37 | 5.78 | 13.82 | 9.98 | 14.28 | 5.81 | 18.09 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 266 | 400 | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | 671 | 694 |
| Expenses | 240 | 359 | 313 | 308 | 299 | 321 | 337 | 376 | 421 | 480 | 522 | 573 | 593 |
| Operating Profit | 26 | 41 | 47 | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 102 | 98 | 101 |
| OPM % | 10% | 10% | 13% | 15% | 18% | 17% | 21% | 20% | 18% | 17% | 16% | 15% | 15% |
| Other Income | 7 | 7 | 2 | 5 | 5 | 11 | 5 | 10 | 22 | 34 | 22 | 33 | 42 |
| Interest | 8 | 10 | 7 | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 | 1 | 1 |
| Depreciation | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 | 14 | 15 |
| Profit before tax | 20 | 33 | 37 | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 | 116 | 128 |
| Tax % | 24% | 28% | 25% | 25% | 22% | 23% | 26% | 28% | 27% | 24% | 25% | 24% | |
| Net Profit | 15 | 24 | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | 88 | 96 |
| EPS in Rs | 9.20 | 14.52 | 14.06 | 17.31 | 24.36 | 25.72 | 31.12 | 34.63 | 36.40 | 46.58 | 41.11 | 43.88 | 48.16 |
| Dividend Payout % | 11% | 7% | 9% | 9% | 6% | 6% | 5% | 4% | 4% | 4% | 4% | 4% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 10.0% | 10.0% | 5.0% |
| Profit CAGR | 7.0% | 7.0% | 14.0% |
Shareholding Pattern
Promoters49.78%
FIIs5.13%
DIIs0.01%
Public45.08%
Promoters49.78%
FIIs4.73%
DIIs0.01%
Public45.49%
Promoters49.78%
FIIs4.70%
DIIs0.01%
Public45.51%
Promoters49.78%
FIIs5.20%
DIIs1.08%
Public43.94%
Promoters49.78%
FIIs4.60%
DIIs0.27%
Public45.36%
Promoters47.00%
FIIs1.27%
Public51.74%
Promoters49.54%
FIIs3.93%
DIIs0.05%
Public46.49%
Promoters49.78%
FIIs5.00%
Public45.23%
Promoters49.78%
FIIs5.20%
DIIs1.08%
Public43.94%
Promoters49.78%
FIIs4.60%
DIIs0.27%
Public45.36%
LINCOLN
Holdings Analysis
Key strengths & risk signals
57
Overall
57
Fundamental
58
Technical
Risks (4)
TOO MUCH PUBLIC HOLDING! 49.57% public ownership - higher volatility risk.
WEAK POSITION! Current price (558.3) is below both moving averages.
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.1% (1 week), 12.4% (1 month), 9.3% (3 months).
POSITIVE YEAR! Stock gained 6.6% in the last year.
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (603.1) is above 200-day average (594.2) - positive signal.
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
APPROACHING OVERSOLD! RSI at 32.8 - watch for reversal.
Fundamental & Technical Analysis
57Overall
57Fundamental
58Technical
Fundamental Breakdown
Growth Quality
16/30
Revenue CAGR: 9.5% (MODERATE, 8/15). Profit CAGR: 6.4% (MODERATE, 8/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.9% profit margin - acceptable profitability.
PEG Valuation
8/10
FAIRLY VALUED! PEG of 1.81 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.32% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 49.57% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
10/10
BULLISH TREND! 50-day average (603.1) is above 200-day average (594.2) - positive signal.
Price Position
2/10
WEAK POSITION! Current price (558.3) is below both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
4/10
POSITIVE YEAR! Stock gained 6.6% in the last year.
Volume Sentiment
20/30
BULLISH SENTIMENT! In last 30 days: 13 up days, 17 down days. Avg volume on up days: 34,604 vs down days: 30,026. Ratio: 1.15x
RSI
4/5
APPROACHING OVERSOLD! RSI at 32.8 - watch for reversal.
52W Range
2/5
LOWER HALF! Trading at 35.8% of 52W range - weakness visible.
Momentum
1/5
NEGATIVE MOMENTUM! Price declined across timeframes - down 4.1% (1 week), 12.4% (1 month), 9.3% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
LINCOLN
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q3FY262026-02-23 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LINCOLN | ₹558.30 | 11.6 | 13.9% | 9.5% | 6.4% | +6.6% | 57 | BREAKDOWN | +30.7% | +212.1% | +15.1% | -5.3% |
| SIGACHI | ₹28.50 | 42.6 | 5.4% | 16.5% | – | -24.4% | 56 | BREAKDOWN | -106.8% | -11.7% | -5.4% | -0.5% |
| BAJAJHCARE | ₹320.00 | 46.2 | 2.8% | -1.8% | -28.4% | -32.8% | 44 | BOUNCE FROM SUPPORT | +16.1% | -159.8% | +11.3% | +8.2% |
| THEMISMED | ₹108.60 | 25.1 | 12.1% | -0.4% | -72.8% | -16.1% | 53 | BREAKDOWN | -273.2% | +176.4% | -10.9% | +13.7% |
| BAFNAPH | ₹418.00 | 127.1 | 5.5% | 9.3% | -0.7% | +152.4% | 66 | BREAKOUT | -97.1% | -96.3% | -23.1% | -37.0% |
| KILITCH | ₹241.60 | 27.4 | 12.7% | 19.2% | 42.4% | +41.9% | 84 | BREAKOUT | -3.3% | -80.0% | +4.2% | -49.9% |
| ANUHPHR | ₹82.00 | 18.6 | 5.7% | 13.5% | 4.3% | +4.0% | 64 | BREAKDOWN | +37.3% | -2.6% | +3.9% | -4.1% |
| ZIMLAB | ₹150.50 | 183.5 | 0.9% | -2.5% | -37.9% | +105.9% | 57 | APPROACHING RESISTANCE | +110.5% | -208.1% | +31.2% | -10.5% |
Data from TradeAlone · Updated daily
No news tagged for LINCOLN yet.
